Latest Research in Carcinoma of the Gastroesophageal Junction

Video

This video highlights the latest research in carcinoma of the gastroesophageal junction, including how using genetic information can help guide treatment.

In this video, Ian Chau, MD, of Royal Marsden Hospital in London, highlights the latest research in carcinoma of the gastroesophageal junction, including a look at immunotherapy in this disease, and how using genetic information can help guide treatment with chemotherapy.

In HER2-positive patients, where trastuzumab is standard in the first-line setting, studies are looking at how to optimize the use of this agent. Chau reviews the findings of two second-line studies that tested switching to a different type of chemotherapy after disease progression while continuing on with trastuzumab.

Recent Videos
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
Related Content
The COMPASSION-37 study is the second international registrational study for cadonilimab following an ongoing trial in hepatocellular carcinoma.

FDA OKs Phase 3 Cadonilimab/Chemo Trial in HER2-Negative Gastric Cancer

Russ Conroy
December 12th 2025
Article

The COMPASSION-37 study is the second international registrational study for cadonilimab following an ongoing trial in hepatocellular carcinoma.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

Qualified surgeons may offer laparoscopic distal gastrectomy as an alternative to open distal gastrectomy among those with clinical T4a gastric cancer.

Laparoscopic Distal Gastrectomy Appears Feasible in T4a Gastric Cancer

Russ Conroy
December 3rd 2025
Article

Qualified surgeons may offer laparoscopic distal gastrectomy as an alternative to open distal gastrectomy among those with clinical T4a gastric cancer.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Results from MATTERHORN showed durvalumab plus FLOT improved EFS and OS compared with placebo plus FLOT in patients with gastric/GEJ cancers.

FDA Approves Durvalumab Plus FLOT in Resectable Gastric/GEJ Cancers

Tim Cortese
November 25th 2025
Article

Results from MATTERHORN showed durvalumab plus FLOT improved EFS and OS compared with placebo plus FLOT in patients with gastric/GEJ cancers.

How Does NALIRIFOX Fit Into the Metastatic PDAC Treatment Paradigm?

How Does NALIRIFOX Fit Into the Metastatic PDAC Treatment Paradigm?

Ariana Pelosci
November 18th 2025
Article

Results from the NAPOLI 3 trial found NALIRIFOX is a viable option for first-line treatment of metastatic pancreatic adenocarcinoma.